148 related articles for article (PubMed ID: 36323434)
21. Augmented replicative capacity of the boosting antigen improves the protective efficacy of heterologous prime-boost vaccine regimens.
Penaloza-MacMaster P; Teigler JE; Obeng RC; Kang ZH; Provine NM; Parenteau L; Blackmore S; Ra J; Borducchi EN; Barouch DH
J Virol; 2014 Jun; 88(11):6243-54. PubMed ID: 24648461
[TBL] [Abstract][Full Text] [Related]
22. Performance of Homologous and Heterologous Prime-Boost Immunization Regimens of Recombinant Adenovirus and Modified Vaccinia Virus Ankara Expressing an Ag85B-TB10.4 Fusion Protein against
Kou Y; Wan M; Shi W; Liu J; Zhao Z; Xu Y; Wei W; Sun B; Gao F; Cai L; Jiang C
J Microbiol Biotechnol; 2018 Jun; 28(6):1022-1029. PubMed ID: 29847865
[TBL] [Abstract][Full Text] [Related]
23. Prime-boost immunization schedules based on influenza virus and vaccinia virus vectors potentiate cellular immune responses against human immunodeficiency virus Env protein systemically and in the genitorectal draining lymph nodes.
Gherardi MM; Nájera JL; Pérez-Jiménez E; Guerra S; García-Sastre A; Esteban M
J Virol; 2003 Jun; 77(12):7048-57. PubMed ID: 12768024
[TBL] [Abstract][Full Text] [Related]
24. Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.
Garber DA; O'Mara LA; Zhao J; Gangadhara S; An I; Feinberg MB
PLoS One; 2009; 4(5):e5445. PubMed ID: 19421328
[TBL] [Abstract][Full Text] [Related]
25. Exosome targeting of tumor antigens expressed by cancer vaccines can improve antigen immunogenicity and therapeutic efficacy.
Rountree RB; Mandl SJ; Nachtwey JM; Dalpozzo K; Do L; Lombardo JR; Schoonmaker PL; Brinkmann K; Dirmeier U; Laus R; Delcayre A
Cancer Res; 2011 Aug; 71(15):5235-44. PubMed ID: 21670078
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of recombinant adenovirus vectors and adjuvanted protein as a heterologous prime-boost strategy using HER2 as a model antigen.
Haq K; Jia Y; Elahi SM; MacLean S; Akache B; Gurnani K; Chattopadhyay A; Nazemi-Moghaddam N; Gilbert R; McCluskie MJ; Weeratna RD
Vaccine; 2019 Nov; 37(47):7029-7040. PubMed ID: 31506193
[TBL] [Abstract][Full Text] [Related]
27. Alphavirus replicon DNA expressing HIV antigens is an excellent prime for boosting with recombinant modified vaccinia Ankara (MVA) or with HIV gp140 protein antigen.
Knudsen ML; Ljungberg K; Tatoud R; Weber J; Esteban M; Liljeström P
PLoS One; 2015; 10(2):e0117042. PubMed ID: 25643354
[TBL] [Abstract][Full Text] [Related]
28. Potent systemic antitumor immunity induced by vaccination with chemotactic-prostate tumor associated antigen gene-modified tumor cell and blockade of B7-H1.
Li N; Qin H; Li X; Zhou C; Wang D; Ma W; Lin C; Zhang Y; Wang S; Zhang S
J Clin Immunol; 2007 Jan; 27(1):117-30. PubMed ID: 17180470
[TBL] [Abstract][Full Text] [Related]
29. Optimized Mucosal Modified Vaccinia Virus Ankara Prime/Soluble gp120 Boost HIV Vaccination Regimen Induces Antibody Responses Similar to Those of an Intramuscular Regimen.
Jones DI; Pollara JJ; Johnson-Weaver BT; LaBranche CC; Montefiori DC; Pickup DJ; Permar SR; Abraham SN; Maddaloni M; Pascual DW; Staats HF
J Virol; 2019 Jul; 93(14):. PubMed ID: 31068425
[TBL] [Abstract][Full Text] [Related]
30. Potent HIV-1-Specific CD8 T Cell Responses Induced in Mice after Priming with a Multiepitopic DNA-TMEP and Boosting with the HIV Vaccine MVA-B.
Perdiguero B; Raman SC; Sánchez-Corzo C; Sorzano COS; Valverde JR; Esteban M; Gómez CE
Viruses; 2018 Aug; 10(8):. PubMed ID: 30104537
[TBL] [Abstract][Full Text] [Related]
31. Development of a Listeria monocytogenes based vaccine against prostate cancer.
Shahabi V; Reyes-Reyes M; Wallecha A; Rivera S; Paterson Y; Maciag P
Cancer Immunol Immunother; 2008 Sep; 57(9):1301-13. PubMed ID: 18273616
[TBL] [Abstract][Full Text] [Related]
32. Intravenous heterologous prime-boost vaccination activates innate and adaptive immunity to promote tumor regression.
Ramirez-Valdez RA; Baharom F; Khalilnezhad A; Fussell SC; Hermans DJ; Schrager AM; Tobin KKS; Lynn GM; Khalilnezhad S; Ginhoux F; Van den Eynde BJ; Leung CSK; Ishizuka AS; Seder RA
Cell Rep; 2023 Jun; 42(6):112599. PubMed ID: 37279110
[TBL] [Abstract][Full Text] [Related]
33. Interleukin-12 (IL-12) enhancement of the cellular immune response against human immunodeficiency virus type 1 env antigen in a DNA prime/vaccinia virus boost vaccine regimen is time and dose dependent: suppressive effects of IL-12 boost are mediated by nitric oxide.
Gherardi MM; Ramírez JC; Esteban M
J Virol; 2000 Jul; 74(14):6278-86. PubMed ID: 10864637
[TBL] [Abstract][Full Text] [Related]
34. Immunity against heterosubtypic influenza virus induced by adenovirus and MVA expressing nucleoprotein and matrix protein-1.
Lambe T; Carey JB; Li Y; Spencer AJ; van Laarhoven A; Mullarkey CE; Vrdoljak A; Moore AC; Gilbert SC
Sci Rep; 2013; 3():1443. PubMed ID: 23485942
[TBL] [Abstract][Full Text] [Related]
35. Heterologous prime-boost regimens using rAd35 and rMVA vectors elicit stronger cellular immune responses to HIV proteins than homologous regimens.
Ratto-Kim S; Currier JR; Cox JH; Excler JL; Valencia-Micolta A; Thelian D; Lo V; Sayeed E; Polonis VR; Earl PL; Moss B; Robb ML; Michael NL; Kim JH; Marovich MA
PLoS One; 2012; 7(9):e45840. PubMed ID: 23049876
[TBL] [Abstract][Full Text] [Related]
36. Immunogenicities of intravenous and intramuscular administrations of modified vaccinia virus Ankara-based multi-CTL epitope vaccine for human immunodeficiency virus type 1 in mice.
Hanke T; Blanchard TJ; Schneider J; Ogg GS; Tan R; Becker M; Gilbert SC; Hill AV; Smith GL; McMichael A
J Gen Virol; 1998 Jan; 79 ( Pt 1)():83-90. PubMed ID: 9460927
[TBL] [Abstract][Full Text] [Related]
37. Heterologous prime-boost immunization co-targeting dual antigens inhibit tumor growth and relapse.
Guo Q; Wang L; Xu P; Geng F; Guo J; Dong L; Bao X; Zhou Y; Feng M; Wu J; Wu H; Yu B; Zhang H; Yu X; Kong W
Oncoimmunology; 2020 Nov; 9(1):1841392. PubMed ID: 33224629
[TBL] [Abstract][Full Text] [Related]
38. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
[TBL] [Abstract][Full Text] [Related]
39. Vaccine efficacy against malaria by the combination of porcine parvovirus-like particles and vaccinia virus vectors expressing CS of Plasmodium.
Rodríguez D; González-Aseguinolaza G; Rodríguez JR; Vijayan A; Gherardi M; Rueda P; Casal JI; Esteban M
PLoS One; 2012; 7(4):e34445. PubMed ID: 22529915
[TBL] [Abstract][Full Text] [Related]
40. Preferential Targeting of Conserved Gag Regions after Vaccination with a Heterologous DNA Prime-Modified Vaccinia Virus Ankara Boost HIV-1 Vaccine Regimen.
Bauer A; Podola L; Mann P; Missanga M; Haule A; Sudi L; Nilsson C; Kaluwa B; Lueer C; Mwakatima M; Munseri PJ; Maboko L; Robb ML; Tovanabutra S; Kijak G; Marovich M; McCormack S; Joseph S; Lyamuya E; Wahren B; Sandström E; Biberfeld G; Hoelscher M; Bakari M; Kroidl A; Geldmacher C
J Virol; 2017 Sep; 91(18):. PubMed ID: 28701395
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
